石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

交易中 08-12 11:40:01

2.420

-0.010

-0.41%

最高2.435	最低2.400	成交量55.80万
今开2.425	昨收2.430	日振幅1.44%
总市值69.96亿	流通市值69.96亿	总股本28.91亿
成交额134.81万	换手率0.02%	流通股本28.91亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":2.42,"timestamp":1786505867875,"preClose":2.43,"halted":0,"volume":558000,"delay":0,"changeRate":-0.0041152263374486546,"floatShares":2891000000,"shares":2891000000,"eps":0.1605,"marketStatus":"交易中","change":-0.01,"latestTime":"08-12 11:40:01","open":2.425,"high":2.435,"low":2.4,"amount":1348120,"amplitude":0.014403,"askPrice":2.42,"askSize":204000,"bidPrice":2.415,"bidSize":32000,"shortable":3,"etf":0,"ttmEps":0.1605,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1786507200000},"marketStatusCode":2,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.43,"dividendRate":0.033058,"openAndCloseTimeList":[[1786498200000,1786507200000],[1786510800000,1786521600000]],"volumeRatio":0.731347,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"2657611419","title":"石四药集团：盐酸齐拉西酮原料药获批上市，瞄准精神分裂症市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2657611419","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657611419?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:30","pubTimestamp":1786095000,"startTime":"0","endTime":"0","summary":"8月7日，石四药集团（02005）发布公告，公司的盐酸齐拉西酮已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。盐酸齐拉西酮是一种新型的非典型广谱抗精神病药，为第二代抗精神病药物，主要用于治疗精神分裂症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073835301183.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073835301183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","LU2460026573.USD","02005","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130926619","title":"石四药集团（02005）盐酸齐拉西酮原料药获国家药监局批准用于上市制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1130926619","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130926619?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:06","pubTimestamp":1786093561,"startTime":"0","endTime":"0","summary":"石四药集团有限公司（02005）8月7日发布自愿公告称，其盐酸齐拉西酮已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。盐酸齐拉西酮是一种新型的非典型广谱抗精神病药，属第二代抗精神病药物，主要用于治疗精神分裂症。  \n  \n公告指出，此次获批有助于完善集团在精神神经领域的原料药配套能力，并进一步丰富集团高活性原料药（HPAPI）产品矩阵。  \n  \n石四药集团表示，发布该自愿公告旨在让股东及潜在投资者了解集团最新业务进展。公告由执行董事兼公司秘书周兴扬代表董事局签署，日期为2026年8月7日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657193576","title":"石四药集团(02005.HK)：盐酸齐拉西酮获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2657193576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657193576?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:05","pubTimestamp":1786093502,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","LU2460026573.USD","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657686346","title":"石四药集团(02005)已取得氯化钾注射液(Ⅱ)(100ml：1.5g)、玻璃酸钠滴眼液 0.3%(0.4ml：1.2mg)等四个产品的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2657686346","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657686346?lang=zh_cn&edition=full","pubTime":"2026-08-06 16:33","pubTimestamp":1786005195,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 公布，集团已取得中国国家药品监督管理局有关以下四个产品的药品生产注册批件，均视同通过一致性评价。一. 氯化钾注射液(Ⅱ): 集团此产品是国内企业第二家获批，属于化学药品第3类，主要用于治疗无法口服补钾时的低钾血症。三. 玻璃酸钠滴眼液 0.1%: 此产品属于化学药品第4类，主要用于干眼症，缓解干眼症状。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476760.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142695282","title":"石四药集团2026年7月股份变动月报表：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1142695282","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142695282?lang=zh_cn&edition=full","pubTime":"2026-08-03 18:01","pubTimestamp":1785751316,"startTime":"0","endTime":"0","summary":"石四药集团于2026年8月3日发布的2026年7月股份变动月报表显示，公司本月无新增股份发行或回购动作，股本结构维持稳定。截至2026年7月31日，法定股本仍为10,000,000,000股，面值每股0.02港元，注册股本合计2亿港元。报告显示，股本始终符合香港联合交易所有限公司有关公众持股量的规定。期内无购回及注销股份的情况。公告由执行董事兼公司秘书周兴扬签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105651738","title":"石四药集团（02005）13个品种16个品规拟中选第十二批全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=1105651738","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105651738?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:55","pubTimestamp":1785750944,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年8月3日公告，在中国第十二批全国药品集中采购招标中，公司投标的13个品种、16个品规产品全部拟中选。公司表示，全国药品集中采购为其业务带来发展机遇，将继续通过原料制剂一体化和规模化生产控制成本，并持续供应高品质产品，以巩固市场竞争力。本公告为自愿披露，旨在使股东及潜在投资者了解公司最新业务进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656327757","title":"石四药集团(02005)投标共十三个品种十六个品规的产品全部拟中选全国药品集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656327757","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656327757?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:53","pubTimestamp":1785750790,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布公告，于最近中国第十二批全国药品集中采购招标中，集团投标共十三个品种十六个品规的产品全部拟中选。全国药品集中采购为集团带来重要发展机遇。集团积极顺应集采政策导向，着力提升产品市场占有率，发挥原料制剂一体化、规模化生产优势，有效控制生产成本，持续供应高品质产品，不断夯实市场竞争实力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)投标共十三个品种十六个品规的产品全部拟中选全国药品集中采购","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LU2460026573.USD","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182061333","title":"石四药集团（02005）获批两款化学药品注册　完善消化及呼吸系统产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=1182061333","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182061333?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:35","pubTimestamp":1785400553,"startTime":"0","endTime":"0","summary":"石四药集团有限公司7月30日发布自愿公告称，公司已获得中国国家药品监督管理局关于两款化学药品的生产注册批件，均视同通过一致性评价。一是西咪替丁注射液，属化学药品第3类，主要用于治疗消化道溃疡。该产品将进一步丰富集团呼吸系统疾病的雾化吸入治疗方案。公司表示，发布本次公告旨在让股东及潜在投资者了解其最新业务进展。上述信息由石四药集团执行董事兼公司秘书周兴扬代表董事局于2026年7月30日发布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655821019","title":"石四药集团(02005)已取得有关西咪替丁注射液(2ml: 0.2g)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2655821019","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655821019?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:32","pubTimestamp":1785400370,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)公布，该集团已取得中国国家药品监督管理局有关西咪替丁注射液(2ml: 0.2g)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。西咪替丁注射液主要用于治疗消化道溃疡。此外，该集团已取得国家药监局有关吸入用乙酰半胱氨酸溶液(3ml: 0.3g)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。吸入用乙酰半胱氨酸溶液主要用于治疗浓稠黏液分泌物过多的呼吸道疾病如：急性支气管炎、慢性支气管炎及其病情恶化者、肺气肿、黏稠物阻塞症以及支气管扩张症。此产品完善集团的祛痰类雾化品种，丰富呼吸系统疾病的雾化吸入治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)已取得有关西咪替丁注射液(2ml: 0.2g)的药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653965710","title":"石四药集团(02005)取得国家药监局有关四个产品的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2653965710","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653965710?lang=zh_cn&edition=full","pubTime":"2026-07-23 16:36","pubTimestamp":1784795798,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布公告，集团已取得中国国家药品监督管理局有关以下四个产品的药品生产注册批件，均属于化学药品第4类，视同通过一致性评价。此产品为肠外营养三腔袋复杂制剂，工艺壁垒较高，主要用于外科术后、肿瘤、ICU 成人患者静脉营养支持。集团系统性布局肠外营养产品平台，覆盖预混三腔袋全合一制剂、营养素、维生素、微量元素及电解质补充剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471390.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)取得国家药监局有关四个产品的药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160168541","title":"石四药集团（02005.HK）获批四款化学药品第4类生产注册 扩充注射液与眼科等产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=1160168541","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160168541?lang=zh_cn&edition=full","pubTime":"2026-07-23 16:36","pubTimestamp":1784795766,"startTime":"0","endTime":"0","summary":"2026年7月23日，石四药集团有限公司发布自愿公告称，已取得中国国家药品监督管理局颁发的四项化学药品第4类药品生产注册批件，并视同通过一致性评价。具体产品及适应症如下：。公司正在布局血滤置换液及腹膜透析液等大容量注射液产品。此前公司8mg规格已获批上市并中标第十一批国家集采。石四药集团表示，上述获批产品将与现有基础输液、氨基酸及脂肪乳系列形成协同，支持公司在医院围手术期及重症营养市场的业务拓展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653405932","title":"石四药集团：钆布醇获批登记为原料药 用于磁共振成像检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2653405932","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653405932?lang=zh_cn&edition=full","pubTime":"2026-07-21 09:56","pubTimestamp":1784598960,"startTime":"0","endTime":"0","summary":"7月21日，石四药集团（02005）发布公告，集团的钆布醇已获得中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。钆布醇是一种磁共振成像造影剂，适用于成人及全年龄段儿童（包括足月新生儿），主要用于全身各部位病变的对比增强磁共振成像（CE-MRI）检查，以及全身各部位的对比增强磁共振血管造影（CE-MRA）检查。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607213814485445.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607213814485445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653244865","title":"石四药集团(02005.HK)：钆布醇获国家药监局批准登记成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2653244865","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653244865?lang=zh_cn&edition=full","pubTime":"2026-07-21 07:59","pubTimestamp":1784591982,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651415715","title":"港股异动 | 石四药集团(02005.HK)涨超4% 非诺贝特酸胆碱缓释胶囊取得药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2651415715","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651415715?lang=zh_cn&edition=full","pubTime":"2026-07-16 13:43","pubTimestamp":1784180609,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158981684","title":"石四药集团（02005）获批非诺贝特酸胆碱135mg缓释胶囊生产注册","url":"https://stock-news.laohu8.com/highlight/detail?id=1158981684","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158981684?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:11","pubTimestamp":1784175117,"startTime":"0","endTime":"0","summary":"石四药集团有限公司7月16日公布，自愿公告显示，公司已取得中国国家药品监督管理局签发的非诺贝特酸胆碱缓释胶囊药品生产注册批件。该产品属于化学药品第4类，可视同通过一致性评价。公司指出，相较传统非诺贝特，非诺贝特酸胆碱具有直接起效、降低肝肾负担、服药不受进食限制，可与他汀类药物安全联合使用等临床优势。石四药集团称，本次获批标志着集团在高端降甘油三酯药物领域的产品迭代取得进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651413889","title":"石四药集团(02005)：非诺贝特酸胆碱缓释胶囊(135mg)取得药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2651413889","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651413889?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:11","pubTimestamp":1784175065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，本集团已取得中国国家药品监督管理局有关非诺贝特酸胆碱缓释胶囊(135mg)的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。非诺贝特酸胆碱缓释胶囊主要在成人控制饮食基础上，用于降低重度高甘油三酯血症患者的甘油三酯水平，以及用于原发性高胆固醇血症或混合型血脂异常患者的治疗。相较传统的非诺贝特，非诺贝特酸胆碱直接起效、肝肾负担更低、服药不受进食限制，且可安全搭配他汀类药品，是临床刚需的高端降甘油三酯换代产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团(02005)：非诺贝特酸胆碱缓释胶囊(135mg)取得药品生产注册批件","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197810239","title":"石四药集团获批生产注册非诺贝特胆碱缓释胶囊（135毫克）","url":"https://stock-news.laohu8.com/highlight/detail?id=1197810239","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197810239?lang=zh_cn&edition=full","pubTime":"2026-07-16 12:10","pubTimestamp":1784175017,"startTime":"0","endTime":"0","summary":"石四药集团宣布，其非诺贝特胆碱缓释胶囊（135毫克）已成功获得药品生产注册批准。这一进展标志着该药物在商业化道路上迈出了关键一步，为集团产品线增添了新的重要成员。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163247546","title":"石四药集团(02005)玛巴洛沙韦原料药获国家药监局批准 登记为上市制剂用API","url":"https://stock-news.laohu8.com/highlight/detail?id=1163247546","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163247546?lang=zh_cn&edition=full","pubTime":"2026-07-13 12:05","pubTimestamp":1783915531,"startTime":"0","endTime":"0","summary":"石四药集团有限公司（02005.HK）7月13日公告称，集团自主研发的玛巴洛沙韦原料药已获中国国家药品监督管理局批准登记，用于在上市制剂中的应用，公司成为国内第三家获批企业。\n公告显示，玛巴洛沙韦主要适用于甲型和乙型流感病毒治疗。公司表示，此次批准旨在向股东及潜在投资者披露最新业务进展。\n本次公告属于自愿信息披露，不涉及财务数据及盈利预测。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163847555","title":"石四药集团获批两款化学药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=1163847555","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163847555?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:36","pubTimestamp":1783672591,"startTime":"0","endTime":"0","summary":"2026年7月10日，石四药集团公告称，已获得中国国家药品监督管理局核发的两项化学药品生产注册批件。石四药集团指出，丙硫氧嘧啶片获批为化学药品第4类产品，视同通过一致性评价，为国内第三家取得该药品批件的企业。连同此前已获批的葡萄糖酸钙氯化钠注射液及葡萄糖酸钙注射液，公司已构建起完整的钙制剂产品系列。公司表示，本次公告属自愿披露，旨在向股东及潜在投资者说明最新业务进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650418323","title":"石四药集团(02005)已取得丙硫氧嘧啶片(50mg)、葡萄糖酸钙氯化钠注射液(50ml:1g/0.3375g)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2650418323","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650418323?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:32","pubTimestamp":1783672374,"startTime":"0","endTime":"0","summary":"丙硫氧嘧啶片主要用于对甲巯咪唑不耐受的各种类型的甲状腺功能亢进症。此外，集团已取得国家药监局有关葡萄糖酸钙氯化钠注射液石四药集团已取得丙硫氧嘧啶片、葡萄糖酸钙氯化钠注射液的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。葡萄糖酸钙氯化钠注射液主要用于治疗急性低钙血症、镁中毒及氟中毒，并与集团已获批的葡萄糖酸钙氯化钠注射液、葡萄糖酸钙氯化钠注射液及葡萄糖酸钙注射液共同构建了钙制剂产品系列。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.0429},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.1821},{"period":"1year","weight":-0.1715},{"period":"ytd","weight":-0.1303}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":0.0611},{"period":"3month","weight":-0.0279},{"period":"6month","weight":-0.051},{"period":"1year","weight":0.03},{"period":"ytd","weight":0.0009}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.008158},{"month":2,"riseRate":0.52381,"avgChangeRate":0.020535},{"month":3,"riseRate":0.666667,"avgChangeRate":0.079315},{"month":4,"riseRate":0.47619,"avgChangeRate":0.030939},{"month":5,"riseRate":0.47619,"avgChangeRate":0.010534},{"month":6,"riseRate":0.47619,"avgChangeRate":0.060362},{"month":7,"riseRate":0.380952,"avgChangeRate":-0.020567},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.015875},{"month":9,"riseRate":0.3,"avgChangeRate":-0.046842},{"month":10,"riseRate":0.45,"avgChangeRate":-0.001891},{"month":11,"riseRate":0.65,"avgChangeRate":0.086083},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009107}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}